"Seciera Meets Primary and Key Secondary Endpoints in Pivotal Trial  Shows Efficacy at  Weeks of Treatment  Sun Pharma is Developing Seciera for Global Markets Sun Pharma announced successful Phase  confirmatory clinical trial results for Seciera cyclosporine A . ophthalmic solution for the treatment of dry eye disease. Seciera is a patented novel proprietary nanomicellar formulation of cyclosporine A .. It is a clear preservativefree aqueous solution. Seciera is being developed by Ocular Technologies a company recently acquired by Sun Pharma. Following this acquisition Sun Pharma owns exclusive worldwide rights to Seciera and is developing it to commercialize for global markets including US Europe and Japan as well as several emerging markets.      Logo httpphotos.prnewswire.comprnh  In this  week multicenter randomized doublemasked vehicle controlled Phase  confirmatory study  dry eye patients were treated either with Seciera or its vehicle.  After  weeks of treatment as compared to vehicle Seciera showed statistically significant improvement in the primary end point Schirmers score a measurement of tear production p.. The demonstration of efficacy by Seciera at  weeks is earlier than other drugs approved for dry eye in the same class. Additionally several key secondary endpoints showed statistically significant improvements compared to vehicle with some showing an even earlier onset of action.  Adverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category. As Sun continues to analyze the data additional significant findings will be shared at upcoming medical conferences. Previously in a completed Phase b clinical trial in  patients Seciera demonstrated a rapid onset of action and was well tolerated by the study population. Based on published data the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset. According to Dilip Shanghvi Managing Director Sun Pharma We are happy to see the early onset of action and strong efficacy results for Seciera. These results are highly encouraging for millions of Dry Eye patients across the globe that have yet to find relief for their condition.  We look forward to discussing these results with US FDA and agree on next steps for the program. I am very excited to see these strong results for Seciera noted Dr. Joseph Tauber Study Investigator and founder of the Tauber Eye Center Kansas City Missouri.  As a clinician who specializes in diagnosing and treating dry eye this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients. Jerry St. Peter Vice President and Head of Sun Ophthalmics added A key strategic imperative for our ophthalmic business is to participate in the rapidly growing underserved and dynamic Dry Eye market which is expected to reach  billion by . Based on this successful confirmatory Phase  trial Seciera has the potential to strengthen our emerging ophthalmics pipeline which includes the recent launch of BromSite and late stage development programs for Xelpros and DexaSite. References  . Sall K Stevenson OD Mundorf TK Reis BL. Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase  Study Group. Ophthalmology.  Apr. PMID  . Sheppard JD Torkildsen GL Lonsdale JD DAmbrosio FA Jr McLaurin EB Eiferman RA Kennedy KS Semba CP. Lifitegrast ophthalmic solution . for treatment of dry eye disease results of the OPUS phase  study. Ophthalmology.  Feb. doi .j.ophtha.... Epub  Nov . PMID  . Tauber J Karpecki P Latkany R Luchs J Martel J Sall K Raychaudhuri A Smith V Semba CP. Lifitegrast Ophthalmic Solution . versus Placebo for Treatment of Dry Eye Disease Results of the Randomized Phase III OPUS Study. Ophthalmology.  Dec. doi .j.ophtha.... Epub  Sep . PMID  . DEWS Research Subcommittee. Research in dry eye report of the Research Subcommittee of the International Dry Eye WorkShop . Ocul Surf. . . Paulsen AJ Cruickshanks KJ Fischer ME et al. Dry eye in the Beaver Dam Offspring Study prevalence risk factors and healthrelated quality of life. Am J Ophthalmol. . . Kantar Health. National Health and Wellness Survey The Global Health and Wellness Report  .http Accessed May . . Market Scope   Comprehensive Report on the Global Dry Eye Products Market December  SOURCE Sun Pharma"